Clinical Trials Logo

Filter by:
NCT ID: NCT05464745 Completed - Healthy Subjects Clinical Trials

Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers

Start date: May 19, 2021
Phase: Phase 1
Study type: Interventional

The present study is a comparative bioavailability study performed to assess bioequivalence between a Test medication (PERINDOPRES® DUO, 8 mg perindopril tert-butylamine / 2.5 mg indapamide tablets manufactured by PrJSC "Pharmaceutical firm "Darnitsa" [Ukraine]) and a Reference medication (marketed medicinal product Noliterax® 10 mg /2.5 mg, 10 mg perindopril arginine / 2.5 mg indapamide film-coated tablets [manufactured by Servier (Ireland) Industries Ltd]) in healthy volunteers.

NCT ID: NCT05460728 Completed - Clinical trials for Traumatic Brain Injury

Dry Needling Effects Post-traumatic Brain Injury

Start date: April 5, 2022
Phase: N/A
Study type: Interventional

Thirty-six years old male with a history of TBI with compromised functionality of the right upper and lower limbs, spasticity, distributed balance, and difficulties performing independent gait has participated in the study. Berg balance scale, 6-minute walk test, modified Ashworth scale, and functional independence measure was used to assess balance, gait, spasticity, and functional intemperance, respectively.

NCT ID: NCT05442801 Completed - Cycloplegia Clinical Trials

Cycloplegic Refraction Among Children

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

The primary outcome of this study is to compare cyclopentolate 1% and tropicamide 1% for cycloplegic refractions in pediatric populations. This will be a prospective double-blinded randomized clinical trial (RCT), multi center, with randomized sequencing of cycloplegic agent; each patient received one agent at one visit, and the other agent in the next visit (2 different visits ≥ 1 week apart) within 3 months.

NCT ID: NCT05375058 Completed - COVID-19 Clinical Trials

Complicated Appendicitis During the COVID-19 Pandemic in Jordan

Start date: March 2, 2019
Phase:
Study type: Observational

Comparing the incidence of complicated appendicitis between two groups, the pandemic and pre-pandemic groups.

NCT ID: NCT05317845 Completed - Clinical trials for Diabetes Mellitus, Type 2

An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa

PACT-MEA
Start date: April 21, 2022
Phase:
Study type: Observational

The study is intended to estimate the proportion and clinical management of people with type 2 diabetes having atherosclerotic cardiovascular diseases or who are at high risk to develop atherosclerotic cardiovascular diseases. Participants will be asked to give information about their health. Partipants will continue normal way of life and will not get any medication other than those prescribed to them by the doctor. The study will last for about 6 months.

NCT ID: NCT05313659 Completed - Clinical trials for Agitation, Emergence

Intramuscular Ketamine Effect on Postnasal Surgery Agitation

Start date: May 11, 2022
Phase: Phase 2
Study type: Interventional

Emergence agitation (EA) is a common complication after nasal surgery. In this study, we aimed to investigate the effect of intramuscular ketamine on EA following septoplasty and open septorhinoplasty (OSRP) when administered at subanesthetic doses at the end of surgery. Sedation and Agitation scores were recorded using The Richmond agitation-sedation score after extubation.

NCT ID: NCT05293977 Completed - Acute Infection Clinical Trials

Short-Term Use of Antibiotics and Adherence Level

Start date: August 3, 2020
Phase: N/A
Study type: Interventional

Objectives: To evaluate the impact of educational intervention on antibiotic short-term adherence . Methods: A prospective randomized controlled study was conducted in a tertiary hospital in Jordan. Adult patients who had an acute infection diagnosis and were prescribed antibiotic pills for short term (< 30 day) at home were included in the study. Patients were recruited and randomly allocated into one of the two groups; control and intervention. Each patient in the intervention group was provided with pharmaceutical education about prescribed antibiotic.

NCT ID: NCT05229796 Completed - Clinical trials for Pharmacokinetic Parameters

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Start date: May 17, 2021
Phase: N/A
Study type: Interventional

Background: The current study is a randomized, open-label, two-period, two-sequence, two-way crossover pharmacokinetic study in healthy Jordanian subjects to evaluate the pharmacokinetics and bioequivalence profile of two formulations of empagliflozin 10-mg under fasting and fed conditions administered orally.; (2) Methods: The plasma concentrations of empagliflozin were determined using High-performance liquid chromatography- Mass Spectrometry/ Mass Spectrometry (HPLC-MS/MS) method. This study included 26 subjects, 26 in each fasting and fed group.

NCT ID: NCT05205707 Completed - COVID-19 Clinical Trials

Association of Circulating ACE2 Levels With COVID-19

Start date: January 1, 2022
Phase:
Study type: Observational

COVID-19 cases are rising substantially in Jordan. Since this is a novel virus, there is still much to be investigated surrounding its pathophysiology in order to attempt to find suitable treatments or better decision-making in the prognosis of the disease. This project aims to identify if soluble angiotensin-converting enzyme (ACE2) can be used as a prognostic factor for COVID-19 severity, which will allow clinicians to manage COVID-19 cases more efficiently. ACE2 is of interest since the coronavirus enters host cells through ACE2 receptors. It can slo be hypothesized that the irus may also bind to soluble ACE2, but without mediating its effects. It si, therefore, expected that those with higher levels of ACE2 would more likely have milder disease. This can potentially help improve survival rate, allowing clinicians to identify the higher-risk patients and monitoring them more closely.

NCT ID: NCT05176730 Completed - Clinical trials for Chronic Kidney Diseases

Mindfulness Meditation For Hemodialysis Patients

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Objective: This study aimed to examine the effects of mindfulness meditation on trait mindfulness, perceived stress, emotion regulation, and quality of life in end-stage renal disease patients undergoing hemodialysis. Method: An experimental repeated measures design was used among a sample of 74 end-stage renal disease patients undergoing hemodialysis at a dialysis center at Jahra hospital, Kuwait. The patients were randomly assigned to the experimental (n=37) and control groups (n=37). The experimental group participated in 30-minute mindfulness meditation sessions (three sessions a week for five weeks) held during their hemodialysis sessions. The dependent variables of both groups were measured at baseline, middle of intervention, and end of intervention using the Mindful Attention Awareness Scale (MAAS), Perceived Stress Scale (PSS), Emotion Regulation Questionnaire (ERQ), and Kidney Disease Quality of Life (KDQOL-36) questionnaire.